AstraZeneca Collaborates with Silence Therapeutics to Develop siRNA Therapeutics Targeting Multiple Diseases

AstraZeneca Collaborates with Silence Therapeutics to Develop siRNA Therapeutics Targeting Multiple Diseases

Shots:

  • Silence to receive $60M upfront, $20M equity investment, $10M as an option fee/ selected target, ~$140M as development milestones, ~$250M as commercial milestones for each target along with royalties on sales of the therapies
  • The multi-target alliance expected to initially work on 5 targets within the first 3yrs. of the collaboration with AstraZeneca to get an option to extend the collaboration for further 5 siRNA therapies targeting CV, renal, metabolic and respiratory diseases
  • The companies will collaborate during the discovery phase while AstraZeneca will lead clinical development and commercialization of molecules, developed during the collaboration. Silence will get an option to co-develop two programs starting from P-II

Click here ­to­ read full press release/ article | Ref: Silence Therapeutics  | Image: AstraZeneca